Menu

Search

  |   Business

Menu

  |   Business

Search

Cascadian Therapeutics Strengthens Management Team with Key Hires, Monique M. Greer and Marc C. Chamberlain, M.D.

SEATTLE, Nov. 28, 2016 -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that the Company strengthened its leadership team with the appointment of Monique M. Greer as Senior Vice President, Investor Relations and Corporate Communications, and Marc C. Chamberlain, M.D., as Medical Director. Ms. Greer will be a member of the Company’s executive committee and will report to Scott D. Myers, Chief Executive Officer of Cascadian Therapeutics. Ms. Greer will have responsibility for external communications, including investor relations, media and digital communications, and advocacy relations. Dr. Chamberlain, a neuro-oncologist, will serve as Medical Director reporting to Dr. Luke Walker, Vice President, Clinical Development. Dr. Chamberlain will be focused on applying his expertise in understanding and treating brain tumors and metastatic diseases in the Central Nervous System (CNS) to Cascadian’s lead late-stage development program evaluating tucatinib, formerly known as ONT-380, in HER2-positive metastatic breast cancer.

“We are pleased to have these talented leaders join Cascadian at this important time in our corporate development,” said Scott D. Myers, Chief Executive Officer. “We believe that their proven leadership and skill sets will benefit us as we continue to advance tucatinib, our lead program for the treatment of patients with HER2-positive breast cancer in patients with or without brain metastases, through late-stage clinical development and towards commercialization.”

Monique M. Greer
Ms. Greer, a veteran biopharmaceutical executive, joins Cascadian Therapeutics with over 20 years of experience driving communications strategies and initiatives. She has played an active role in several successful financing rounds and helped launch multiple drugs in the U.S. and Europe. Ms. Greer was most recently Senior Vice President of Corporate Communications and Investor Relations at CTI BioPharma Corp., where she led the company’s corporate, investor and product communications. Ms. Greer also served in similar functions at Allos Therapeutics, Inc. (acquired by Spectrum Pharmaceuticals); WCG, a global communications agency; Dendreon Corporation and Heska Corporation.

Marc C. Chamberlain, M.D.
Dr. Chamberlain was most recently Professor of Neurology and Neurological Surgery at the University of Washington, Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance in Seattle, Washington. Dr. Chamberlain has developed many of the methods used today in evaluating and managing neoplastic meningitis. Dr. Chamberlain has focused increasingly on clinical trials for primary brain tumors, hoping to achieve new and better therapies. He has published his work in more than 350 scientific papers in peer-reviewed publications. Dr. Chamberlain received his medical degree in from Columbia University, College of Physicians and Surgeons in New York.

About Cascadian Therapeutics

Cascadian Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative product candidates for the treatment of cancer. The lead product candidate, tucatinib, also known as ONT-380, is an oral, selective small molecule HER2 inhibitor. Preliminary results from two ongoing Phase 1b studies of tucatinib in combination showed promising systemic activity, a favorable safety profile and encouraging activity against brain metastases. Cascadian Therapeutics is conducting a randomized, double-blind, placebo-controlled Phase 2 study called HER2CLIMB. The study is evaluating tucatinib versus placebo in combination with capecitabine and trastuzumab in late stage HER2+ breast cancer patients, with and without brain metastases, who have previously been treated with a taxane, trastuzumab, pertuzumab and T-DM1. Additional details can be found at www.clinicaltrials.gov (Identifier: NCT02614794) or www.HER2CLIMB.com. For more information and to sign up for email alerts or RSS feeds, please visit www.cascadianrx.com.

Contacts:
Monique Greer
Cascadian Therapeutics
206-801-2107
mgreer@cascadianrx.com

Media Contact:
Brad Miles
BMC Communications
917-570-7340
bmiles@bmccommunications.com

Primary Logo

  • ET PRO
  • Market Data

Market-moving news and views, 24 hours a day >

February 20 11:00 UTC Released

GBCBI Trends - Orders

Actual

8 bln EUR

Forecast

4 bln EUR

Previous

5 bln EUR

February 20 07:00 UTC Released

TRConsumer Confidence*

Actual

65.7 %

Forecast

Previous

66.90 %

February 20 13:30 UTC 1919m

TRCentral Govt Debt Stock*

Actual

Forecast

Previous

0.2 bln TRY

February 20 13:30 UTC 1919m

EZWholesale Trade MM

Actual

Forecast

Previous

0.2 %

February 20 13:30 UTC 1919m

CAWholesale Trade MM

Actual

Forecast

0.7 %

Previous

0.2 %

February 20 14:30 UTC 7979m

EZWholesale Trade MM

Actual

Forecast

Previous

759.6 %

February 20 14:30 UTC 7979m

JPCentral Govt Debt Stock*

Actual

Forecast

Previous

759.6 bln TRY

February 20 15:00 UTC 109109m

EZWholesale Trade MM

Actual

Forecast

-4.9 %

Previous

-4.9 %

February 20 15:00 UTC 109109m

FRConsumer Confid. Flash

Actual

Forecast

-4.9 %

Previous

-4.9 %

February 21 00:30 UTC 679679m

JPCentral Govt Debt Stock*

Actual

Forecast

Previous

52.7 bln TRY

Close

Welcome to EconoTimes

Sign up for daily updates for the most important
stories unfolding in the global economy.